InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.130 0.01 (7.14%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$17 ARG-007 Phase 2 Clinical Trial Update 19 Jul 2023 8:23AM $0.375 $0.130 fallen by 65.33%
$17 Ceasing to be a substantial holder 17 Jul 2023 8:15AM $0.345 $0.130 fallen by 62.32%
$17 ARG-007 Protects Brain Cells in Moderate TBI Model 22 Jun 2023 8:19AM $0.360 $0.130 fallen by 63.89%
$17 Becoming a substantial holder 20 Jun 2023 8:21AM $0.380 $0.130 fallen by 65.79%
$17 Becoming a substantial holder 13 Jun 2023 5:34PM $0.370 $0.130 fallen by 64.86%
$17 Application for quotation of securities - AGN 13 Jun 2023 9:33AM $0.390 $0.130 fallen by 66.67%
$17 Notification regarding unquoted securities - AGN 9 Jun 2023 10:37AM $0.390 $0.130 fallen by 66.67%
$17 Cleansing Notice 9 Jun 2023 10:21AM $0.390 $0.130 fallen by 66.67%
$17 Application for quotation of securities - AGN 9 Jun 2023 10:19AM $0.390 $0.130 fallen by 66.67%
$17 Release of Restricted Securities From Escrow 5 Jun 2023 4:33PM $0.385 $0.130 fallen by 66.23%
$17 Proposed issue of securities - AGN 2 Jun 2023 9:29AM $0.425 $0.130 fallen by 69.41%
$17 Argenica Successfully Completes $4.0m Placement 2 Jun 2023 9:29AM $0.425 $0.130 fallen by 69.41%
$17 Trading Halt 31 May 2023 9:20AM $0.425 $0.130 fallen by 69.41%
$17 Final Phase1 Clinical Trial Report 15 May 2023 8:22AM $0.420 $0.130 fallen by 69.05%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2023 8:02AM $0.445 $0.130 fallen by 70.79%
$17 Latest Preclinical HIE Study Results 20 Apr 2023 8:13AM $0.460 $0.130 fallen by 71.74%
$17 Significant Non-Dilutive Funding For Preclinical HIE Studies 30 Mar 2023 9:28AM $0.420 $0.130 fallen by 69.05%
$17 Interim Phase 1 Safety Report Confirms Safety of ARG-007 6 Mar 2023 8:16AM $0.440 $0.130 fallen by 70.45%
$17 Half Yearly Report and Accounts 28 Feb 2023 7:51AM $0.430 $0.130 fallen by 69.77%
$17 Non-Dilutive Funding Received to Progress Alzheimers Studies 22 Feb 2023 8:06AM $0.445 $0.130 fallen by 70.79%
$17 Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers 9 Feb 2023 8:16AM $0.405 $0.130 fallen by 67.90%
$17 Investor Presentation 2 Feb 2023 8:19AM $0.430 $0.130 fallen by 69.77%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 7:42AM $0.435 $0.130 fallen by 70.11%
$17 Argenica Awarded $1.2m CRC-P Grant for TBI Project 20 Jan 2023 9:15AM $0.445 $0.130 fallen by 70.79%
$17 Successful Completion of Phase 1 Clinical Trial Dosing 21 Dec 2022 8:20AM $0.455 $0.130 fallen by 71.43%

176 - 200 of 297 results

Page 8 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.